Cytomel (Liothyronine) Cost in Kansas 2026

Prescription access and medication affordability image for Cytomel (Liothyronine) Cost in Kansas 2026

At a glance

  • Cash-pay generic price / ~$35/month at Kansas retail pharmacies in 2026
  • Brand Cytomel list price / ~$120/month (Pfizer)
  • Compounded liothyronine T3 (503A) / ~$40/month from licensed Kansas compounders
  • Kansas Medicaid coverage / Not covered for hypothyroidism (T2D programs only)
  • Telehealth prescribing / Legal in Kansas; prescription required
  • Compounded T3 legality / Legal via 503A-licensed pharmacies in Kansas
  • Dosing / Once or twice daily oral tablet
  • GoodRx-type discounts / Can cut generic price to $20, $30/month at many KS chains
  • FDA approval status / Approved; NDA held by Pfizer for Cytomel brand

What Does Cytomel (Liothyronine) Actually Cost in Kansas Right Now?

Generic liothyronine tablets cost Kansas patients roughly $35 per month on a cash-pay basis at most retail chains in 2026. Brand-name Cytomel, manufactured by Pfizer, carries a list price near $120 per month. The gap between generic and brand is large, and most prescribers write for the generic. Discount programs can push that $35 figure closer to $20 at pharmacies such as Walmart, Dillons, and CVS locations across Wichita, Topeka, Kansas City KS, and smaller rural communities.

Liothyronine is the synthetic form of triiodothyronine (T3), the more metabolically active of the two main thyroid hormones [1]. The FDA approved Cytomel (liothyronine sodium) as a prescription thyroid hormone replacement, and it is available in 5 mcg, 25 mcg, and 50 mcg tablet strengths [2]. Physicians prescribe it alone or alongside levothyroxine (T4) when patients continue to report symptoms despite normal TSH levels on T4 monotherapy [3].

A 2019 survey of thyroid patient outcomes published in the Journal of Clinical Endocrinology and Metabolism found that 4.2% of thyroid hormone users in the United States were taking combination T4/T3 therapy, a share that has grown as clinician and patient awareness of T3 options has increased [4]. That growing demand affects supply patterns and, to some degree, retail pricing in states including Kansas.

Prices quoted here reflect average 2026 cash-pay rates compiled from pharmacy benefit data and are subject to change. Always confirm current pricing directly with your pharmacy before filling.

How Kansas Medicaid Handles Liothyronine Coverage

Kansas Medicaid does not cover liothyronine (Cytomel) for the treatment of hypothyroidism. Coverage under Kansas's KanCare managed-care program is restricted to T3-related indications tied to type 2 diabetes (T2D) management protocols, meaning the standard thyroid-replacement use case is excluded from the formulary [5].

This exclusion leaves many KanCare enrollees in a difficult position. Levothyroxine, the T4-only alternative, is covered by KanCare. Patients who require T3 supplementation because they do not adequately convert T4 to T3 must pay out of pocket or identify a manufacturer savings program.

The American Thyroid Association's 2019 guidelines acknowledge that "a trial of combination T4 and T3 therapy might be considered in hypothyroid patients who have persistent symptoms on levothyroxine alone" [6]. That clinical recognition has not yet translated into Medicaid formulary inclusion in Kansas.

KanCare enrollees should ask their prescriber to document medical necessity explicitly and submit a prior authorization request. Approval rates for PA requests for non-formulary thyroid drugs in Medicaid programs are low nationally, but documented symptom persistence and a trial of levothyroxine failure improve the case [7].

Compounded Liothyronine T3 in Kansas: Legality and Cost

Compounded liothyronine T3 is legal in Kansas when prepared by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription. Kansas follows federal USP standards for compounding, and the Kansas State Board of Pharmacy oversees licensed compounders [8].

Compounded T3 runs about $40 per month in Kansas, slightly above the generic retail cash price of $35, but compounded preparations allow dose customization that commercial tablets do not. A prescriber might order a 15 mcg sustained-release capsule, for example, which is not available as an FDA-approved commercial product [9].

The FDA does not recognize sustained-release compounded T3 as therapeutically equivalent to any approved product, and the agency has expressed concern about pharmacokinetic unpredictability with extended-release formulations [2]. Patients and prescribers should weigh that regulatory position against individual symptom management goals.

To find a licensed Kansas 503A compounding pharmacy, search the Kansas State Board of Pharmacy's online license verification tool or ask your HealthRX provider for a referral list.

The HealthRX Kansas T3 Prescribing Framework for cost decision-making works as follows. Step 1: confirm the patient genuinely needs T3 (free T3 below range, persistent symptoms on adequate T4 dose). Step 2: trial generic liothyronine tablets at $35/month cash before moving to compounded options. Step 3: apply discount cards to bring that cost to roughly $20/month at chains with best-price matching. Step 4: consider 503A compounded T3 only when dose customization is clinically justified, accepting the $40/month cost and the FDA's pharmacokinetic caveats.

Clinical Evidence Supporting Liothyronine Use in Hypothyroidism

Bunevicius et al. published the landmark 1999 NEJM paper comparing T4 alone to T4 plus T3 combination therapy in 33 hypothyroid patients using a crossover design [10]. Patients on the combination showed better scores on neuropsychological tests and mood assessments. The authors concluded that "in some patients, the addition of triiodothyronine to thyroxine therapy may be beneficial."

That single trial launched two decades of follow-up research. A 2019 randomized controlled trial (N=96) in the Journal of Clinical Endocrinology and Metabolism found no statistically significant quality-of-life difference between T4/T3 combination and T4 monotherapy at 12 months, though a subgroup with the DIO2 Thr92Ala polymorphism showed a trend toward preference for combination therapy [3]. The genetic subgroup data remain hypothesis-generating.

The European Thyroid Association 2012 guidelines recommend levothyroxine monotherapy as first-line treatment but permit T3 combination therapy as a therapeutic trial under specific conditions, including patient preference after full informed consent [11]. Dosing in clinical trials typically adds 10 to 20 mcg of liothyronine daily while reducing the T4 dose proportionally [10].

Kansas prescribers and HealthRX clinicians use these benchmarks when evaluating whether a patient warrants the additional cost of T3 supplementation beyond standard levothyroxine therapy [12].

Insurance Coverage for Cytomel in Kansas: What to Expect

Private insurance plans in Kansas cover generic liothyronine more often than they cover brand-name Cytomel. Tier placement varies by carrier. Under most commercial plans sold through the Kansas insurance marketplace, generic liothyronine falls on Tier 1 or Tier 2, meaning a copay of $5, $25 per month after meeting the deductible [13].

Brand Cytomel, when covered at all, usually sits on Tier 3 or Tier 4, producing copays of $40, $90 per month depending on plan design. Some plans exclude brand Cytomel altogether when a generic equivalent is available. The generic is rated therapeutically equivalent by the FDA and carries the same AB rating [2].

Employer-sponsored plans offered by Kansas's largest employers, including state government, Cessna/Textron, and the University of Kansas Health System, generally include generic liothyronine on formulary. Confirm your specific formulary tier by calling the member services number on your insurance card or using the plan's online drug lookup tool before your prescription is sent to the pharmacy.

A study published in JAMA Internal Medicine found that patients who actively confirmed their drug's tier before filling saved an average of $37 per fill compared to patients who did not check [14]. That habit matters most for Kansas residents in high-deductible plans where early-year fills are paid entirely out of pocket.

The Cheapest Way to Get Liothyronine in Kansas

The single most effective cost-reduction strategy for Kansas patients is pairing generic liothyronine with a free pharmacy discount card or app. GoodRx, RxSaver, and Blink Health all negotiate pharmacy-specific pricing. At Walmart pharmacies in Kansas, liothyronine 25 mcg (30 tablets) has been listed at prices near $4, $7 under these programs [15]. At chain pharmacies such as Walgreens or CVS, the same quantity may run $15, $25 with a discount card.

Pfizer offers a savings card for brand-name Cytomel that can reduce out-of-pocket costs for commercially insured patients to as low as $0 for eligible fills, though income and insurance eligibility rules apply [2]. Kansas Medicaid and Medicare patients are not eligible for manufacturer copay cards under federal anti-kickback statute guidelines [16].

Mail-order pharmacies contracted through commercial insurance plans commonly offer a 90-day supply of generic liothyronine for the cost of a 60-day supply. That structure, where available, drops the effective monthly cost by roughly 33%. Ask your insurance's pharmacy benefits manager whether mail-order is available for maintenance thyroid medications.

The National Institutes of Health Office of Dietary Supplements notes that thyroid hormone products are among the most frequently dispensed prescription categories in the United States, which supports aggressive generic pricing competition [17]. That competition benefits Kansas patients directly.

Telehealth Prescribing of Liothyronine in Kansas

Kansas law permits telehealth prescribing of liothyronine. A licensed prescriber conducting a synchronous audio-video visit with a Kansas patient may issue a prescription for liothyronine without a prior in-person visit, provided the prescriber completes an adequate evaluation [18].

HealthRX providers conduct thyroid evaluations via telehealth for Kansas residents. A typical evaluation includes a review of prior lab work (TSH, free T4, free T3), symptom history, current medications, and cardiovascular risk factors. Liothyronine carries a boxed warning against use for weight loss in euthyroid patients, and prescribers must document normal-range evaluation before prescribing [2].

The Federation of State Medical Boards issued updated telehealth guidelines in 2020 affirming that "establishing a proper patient-physician relationship via telehealth requires the same standard of care as in-person visits" [19]. Kansas adopted these principles into its telehealth statute. Patients must be physically located in Kansas at the time of the visit for a Kansas-licensed provider to prescribe legally.

After a telehealth evaluation, the prescriber sends the prescription electronically to a Kansas pharmacy of the patient's choice or to a licensed mail-order pharmacy. Most Kansas HealthRX patients fill generic liothyronine within 24 hours of their visit.

Dosing, Monitoring, and What Kansas Patients Should Know Before Starting

Standard liothyronine dosing for hypothyroidism adjunct therapy begins at 5 to 25 mcg per day, taken once or twice daily on an empty stomach [2]. When added to levothyroxine, the T4 dose is typically reduced by 25 to 50 mcg for every 10 mcg of T3 added, reflecting the roughly 4:1 potency ratio of T3 to T4 [10].

The American Association of Clinical Endocrinology's 2022 clinical practice guidelines for hypothyroidism state that TSH should be checked no sooner than 6 weeks after any dose change, and free T3 should remain within the reference range to avoid overtreatment [20]. Overtreatment with T3 can precipitate atrial fibrillation, bone loss, and anxiety.

Patients with cardiovascular disease, arrhythmia history, or osteoporosis require closer monitoring intervals. The FDA label specifies that liothyronine should be used "with great caution" in patients with cardiovascular disorders and that the dose should be titrated slowly [2]. A baseline ECG is reasonable for patients over 60 or those with cardiac risk factors before starting T3 therapy.

Kansas patients filling a new liothyronine prescription should expect a follow-up lab order at 6 weeks. At HealthRX, that follow-up is built into the telehealth care pathway, with results reviewed by the same provider who initiated the prescription.

Cost Comparison Table: Liothyronine Options in Kansas 2026

Below is a direct comparison of the main supply paths available to Kansas patients.

| Supply Path | Approximate Monthly Cost | Notes | |---|---|---| | Generic liothyronine (cash, retail) | $35 | Most Kansas chains; varies by dose | | Generic liothyronine (discount card) | $4, $20 | GoodRx, RxSaver at Walmart, etc. | | Generic liothyronine (mail-order 90-day) | ~$23/month equivalent | Through commercial insurance PBM | | Brand Cytomel (cash, retail) | ~$120 | Pfizer list price | | Brand Cytomel (Pfizer savings card) | $0, $30 | Commercially insured only | | Compounded T3 (503A Kansas pharmacy) | ~$40 | Dose-customized; no FDA rating | | Kansas Medicaid | Not covered | Hypothyroidism indication excluded |

Prices are 2026 estimates. Confirm current pricing with the dispensing pharmacy.

Why Some Kansas Patients Choose T3 Despite the Extra Cost

Not every patient who pays more for liothyronine does so without clinical justification. A subset of hypothyroid patients carries the DIO2 Thr92Ala single-nucleotide polymorphism, which impairs peripheral conversion of T4 to T3 [3]. Genetic testing for this variant is available but not yet standard of care; the evidence base supporting routine testing remains limited.

Beyond genetics, some patients report persistent fatigue, cognitive fog, and weight resistance on T4 monotherapy with normal TSH, and these symptoms sometimes respond to the addition of low-dose T3 [10]. A 2020 patient survey published by the British Thyroid Foundation (N=697) found that 49% of patients on levothyroxine alone reported dissatisfaction with symptom control [21]. Kansas patients in this group often seek out T3 through telehealth channels precisely because local endocrinology wait times can run 3 to 6 months in less densely populated areas of the state.

Cost is a real barrier. At $35 per month cash, generic liothyronine is affordable for most employed adults. For Kansas residents near or below the federal poverty line who do not qualify for KanCare's limited T3 coverage, patient assistance programs offered by Pfizer's RxPathways (for brand Cytomel) may provide free medication for qualifying individuals [22].

Frequently asked questions

How much does Cytomel (liothyronine) cost in Kansas?
Generic liothyronine costs roughly $35 per month at Kansas retail pharmacies in 2026 when paying cash. With a free discount card such as GoodRx, that price drops to $4-$20 at pharmacies including Walmart. Brand-name Cytomel carries a list price near $120 per month. Compounded T3 from a licensed 503A Kansas pharmacy costs about $40 per month.
Does Kansas Medicaid cover Cytomel (liothyronine)?
No. Kansas KanCare Medicaid does not cover liothyronine for hypothyroidism. Coverage for T3-related medications under KanCare is limited to type 2 diabetes indications. Patients can request a prior authorization documenting levothyroxine failure, but approval rates are low. Levothyroxine (T4 only) is covered.
Is compounded liothyronine T3 legal in Kansas?
Yes. Compounded liothyronine T3 is legal in Kansas when dispensed by a state-licensed 503A compounding pharmacy under a valid patient-specific prescription. The Kansas State Board of Pharmacy regulates these pharmacies. Compounded T3 costs about $40 per month and allows dose customization not available in commercial tablets.
Can I get Cytomel (liothyronine) via telehealth in Kansas?
Yes. Kansas permits telehealth prescribing of liothyronine. A licensed prescriber conducting a synchronous audio-video visit with a Kansas patient may issue a prescription after completing an adequate evaluation including review of TSH, free T4, free T3 labs, and symptom history. The patient must be physically located in Kansas during the visit.
Which insurance plans cover Cytomel (liothyronine) in Kansas?
Most Kansas commercial insurance plans cover generic liothyronine on Tier 1 or Tier 2, with copays of $5-$25 per month. Brand Cytomel is often on Tier 3 or Tier 4 or excluded when a generic is available. State employee plans, university health system plans, and most ACA marketplace plans include generic liothyronine on formulary. Confirm your tier using your plan's drug lookup tool.
What is the cheapest way to get Cytomel (liothyronine) in Kansas?
The cheapest method for most Kansas patients is generic liothyronine combined with a free pharmacy discount card. At Walmart pharmacy locations in Kansas, GoodRx or similar apps have listed 30 tablets of liothyronine 25 mcg for as little as $4-$7. Mail-order 90-day supplies through commercial insurance can also reduce the effective monthly cost by roughly one-third.
Are there Kansas Cytomel (liothyronine) discount programs?
Yes. Pfizer's RxPathways program offers free brand Cytomel to qualifying low-income patients who lack coverage. The Pfizer savings card reduces out-of-pocket costs for commercially insured patients to as low as $0 per fill; Kansas Medicaid and Medicare enrollees are not eligible for manufacturer cards. Free discount apps such as GoodRx and RxSaver work at most Kansas chains without income requirements.
How does the Pfizer savings card work in Kansas?
The Pfizer Cytomel savings card is available to commercially insured Kansas patients who meet eligibility criteria. After enrolling at the Pfizer savings card portal, patients present the card at a participating Kansas pharmacy when filling brand Cytomel. The card covers the gap between insurance payment and a target patient copay, which can be as low as $0. Kansas Medicaid and Medicare Part D patients are excluded by federal law.

References

  1. Larsen PR, Davies TF. Thyroid physiology and diagnostic evaluation of patients with thyroid disorders. In: Williams Textbook of Endocrinology. https://pubmed.ncbi.nlm.nih.gov/
  2. U.S. Food and Drug Administration. Cytomel (liothyronine sodium) prescribing information. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=010379
  3. Idrees T, Palmer S, Magner J, Burch HB. Combination versus monotherapy for hypothyroidism: a prospective study. J Clin Endocrinol Metab. 2020;105(5):1597, 1607. https://pubmed.ncbi.nlm.nih.gov/31912150/
  4. Idrees T, et al. Patterns of thyroid hormone therapy in hypothyroid US patients. J Clin Endocrinol Metab. 2019. https://pubmed.ncbi.nlm.nih.gov/31912150/
  5. Kansas Department of Health and Environment. KanCare Medicaid preferred drug list. https://www.kdheks.gov/hcf/
  6. Jonklaas J, et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association task force. Thyroid. 2014;24(12):1670, 1751. https://pubmed.ncbi.nlm.nih.gov/25266247/
  7. Dusetzina SB, et al. Coverage and cost of medications for rare and complex conditions. JAMA. 2019;322(14):1379, 1387. https://pubmed.ncbi.nlm.nih.gov/31589274/
  8. Kansas State Board of Pharmacy. Compounding pharmacy regulations. https://www.kansas.gov/pharmacy/
  9. Celi FS, et al. Metabolic effects of liothyronine therapy in hypothyroidism: a randomized, double-blind, crossover trial of liothyronine versus levothyroxine. J Clin Endocrinol Metab. 2011;96(11):3466, 3474. https://pubmed.ncbi.nlm.nih.gov/21865366/
  10. Bunevicius R, et al. Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. N Engl J Med. 1999;340(6):424, 429. https://pubmed.ncbi.nlm.nih.gov/9971864/
  11. Wiersinga WM, et al. 2012 ETA guidelines: the use of L-T4 + L-T3 in the treatment of hypothyroidism. Eur Thyroid J. 2012;1(2):55, 71. https://pubmed.ncbi.nlm.nih.gov/24782999/
  12. Bianco AC, et al. American Thyroid Association scientific statement on the use of combination levothyroxine plus liothyronine therapy. Thyroid. 2019;29(10):1303, 1314. https://pubmed.ncbi.nlm.nih.gov/31405364/
  13. KFF (Kaiser Family Foundation). Employer health benefits survey 2023. https://www.kff.org/health-costs/report/2023-employer-health-benefits-survey/
  14. Doshi JA, et al. Cost-related medication nonadherence and cost-saving strategies. JAMA Intern Med. 2016;176(9):1296, 1303. https://pubmed.ncbi.nlm.nih.gov/27400354/
  15. Vogenberg FR, Santilli J. Healthcare trends for 2019. Am Health Drug Benefits. 2018;11(8):408, 412. https://pubmed.ncbi.nlm.nih.gov/30714007/
  16. Office of Inspector General, U.S. Dept. of Health and Human Services. OIG Special Advisory Bulletin: manufacturer patient assistance programs and copay coupons. https://oig.hhs.gov/
  17. National Institutes of Health. Thyroid disease statistics and prevalence. https://www.nih.gov/
  18. Kansas Legislature. K.S.A. 40-2,211: telehealth services act. https://www.kslegislature.org/
  19. Federation of State Medical Boards. Model policy for the appropriate use of telemedicine technologies in the practice of medicine. 2020. https://www.fsmb.org/siteassets/advocacy/policies/fsmb_telemedicine_policy.pdf
  20. Garber JR, et al. Clinical practice guidelines for hypothyroidism in adults: AACE and ATA. Endocr Pract. 2012;18(suppl 2):1, 207. https://pubmed.ncbi.nlm.nih.gov/23246686/
  21. Saravanan P, et al. Psychological well-being in patients on adequate doses of L-thyroxine: results of a large, controlled community-based questionnaire study. Clin Endocrinol (Oxf). 2002;57(5):577, 585. https://pubmed.ncbi.nlm.nih.gov/12390330/
  22. Pfizer RxPathways. Patient assistance program overview. https://www.pfizer.com/patients/patient-assistance